FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2967066402> ?p ?o ?g. }

• W2967066402 endingPage "2312" @default.
• W2967066402 startingPage "2305" @default.
• W2967066402 abstract "Two randomized controlled trials (reSURFACE 1 and 2) have demonstrated the effectiveness of tildrakizumab, a high-affinity, humanized, IgG1κ, anti-interleukin-23 monoclonal antibody, for treating moderate-to-severe plaque psoriasis in the first 28 weeks.To examine the efficacy of tildrakizumab and its impact on quality of life (QoL) in patients with different levels of week-28 Psoriasis Area and Severity Index (PASI) improvement.Patients treated with tildrakizumab 100 mg or 200 mg from baseline to week 28 were pooled from reSURFACE 1 and reSURFACE 2 and classified into five mutually exclusive week-28 PASI improvement groups for each dose: PASI 0-49, 50-74, 75-89, 90-99 and 100. Mean PASI improvement and Dermatology Life Quality Index (DLQI) 0/1 over time were examined for each group.Of 1156 patients, 575 were in the 100-mg and 578 in the 200-mg cohorts, respectively. At week 28, 8.3%, 14.3%, 23.8%, 30.4% and 23.1% in the 100-mg and 4.0%, 18.1%, 19.6%, 29.1% and 29.3% in the 200-mg cohort achieved PASI < 50, 50-74, 75-89, 90-99 and 100, respectively. Patients with PASI < 50 at week 28 could be identified as early as week 8, and those with week-28 PASI ≥ 90 had approximately 50% PASI improvement by week 4. Among patients achieving PASI > 50 at week 28 who continued the same dose of tildrakizumab to week 52, mean PASI improvement was maintained or improved over time. Similar results were observed for both doses. Higher proportions of patients achieved DLQI 0/1 in higher week-28 PASI groups, and DLQI 0/1 was maintained or improved to week 52. However, not all patients with PASI 100 had DLQI 0/1.Patients unlikely to respond to tildrakizumab could be identified by week 8, and those likely to achieve a PASI ≥ 90 response could be identified as early as week 4. Week-28 PASI improvement level correlated with QoL improvement." @default.
• W2967066402 created "2019-08-22" @default.
• W2967066402 creator A5000478173 @default.
• W2967066402 creator A5000572878 @default.
• W2967066402 creator A5006526834 @default.
• W2967066402 creator A5008286260 @default.
• W2967066402 creator A5025829423 @default.
• W2967066402 creator A5061354641 @default.
• W2967066402 creator A5067889803 @default.
• W2967066402 creator A5080223253 @default.
• W2967066402 creator A5080237247 @default.
• W2967066402 creator A5083512745 @default.
• W2967066402 date "2019-09-11" @default.
• W2967066402 modified "2023-10-18" @default.
• W2967066402 title "Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials" @default.
• W2967066402 cites W1754228489 @default.
• W2967066402 cites W1968179324 @default.
• W2967066402 cites W1968405676 @default.
• W2967066402 cites W1973354423 @default.
• W2967066402 cites W2012581664 @default.
• W2967066402 cites W2087624875 @default.
• W2967066402 cites W2103120331 @default.
• W2967066402 cites W2107432039 @default.
• W2967066402 cites W2160630176 @default.
• W2967066402 cites W2418506270 @default.
• W2967066402 cites W2589858067 @default.
• W2967066402 cites W2623888527 @default.
• W2967066402 cites W2786492839 @default.
• W2967066402 cites W65111514 @default.
• W2967066402 doi "https://doi.org/10.1111/jdv.15862" @default.
• W2967066402 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6899626" @default.
• W2967066402 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31407394" @default.
• W2967066402 hasPublicationYear "2019" @default.
• W2967066402 type Work @default.
• W2967066402 sameAs 2967066402 @default.
• W2967066402 citedByCount "34" @default.
• W2967066402 countsByYear W29670664022019 @default.
• W2967066402 countsByYear W29670664022020 @default.
• W2967066402 countsByYear W29670664022021 @default.
• W2967066402 countsByYear W29670664022022 @default.
• W2967066402 countsByYear W29670664022023 @default.
• W2967066402 crossrefType "journal-article" @default.
• W2967066402 hasAuthorship W2967066402A5000478173 @default.
• W2967066402 hasAuthorship W2967066402A5000572878 @default.
• W2967066402 hasAuthorship W2967066402A5006526834 @default.
• W2967066402 hasAuthorship W2967066402A5008286260 @default.
• W2967066402 hasAuthorship W2967066402A5025829423 @default.
• W2967066402 hasAuthorship W2967066402A5061354641 @default.
• W2967066402 hasAuthorship W2967066402A5067889803 @default.
• W2967066402 hasAuthorship W2967066402A5080223253 @default.
• W2967066402 hasAuthorship W2967066402A5080237247 @default.
• W2967066402 hasAuthorship W2967066402A5083512745 @default.
• W2967066402 hasBestOaLocation W29670664021 @default.
• W2967066402 hasConcept C126322002 @default.
• W2967066402 hasConcept C159110408 @default.
• W2967066402 hasConcept C16005928 @default.
• W2967066402 hasConcept C168563851 @default.
• W2967066402 hasConcept C2776173921 @default.
• W2967066402 hasConcept C2777011040 @default.
• W2967066402 hasConcept C2779951463 @default.
• W2967066402 hasConcept C2780564577 @default.
• W2967066402 hasConcept C3020604521 @default.
• W2967066402 hasConcept C71924100 @default.
• W2967066402 hasConcept C90924648 @default.
• W2967066402 hasConceptScore W2967066402C126322002 @default.
• W2967066402 hasConceptScore W2967066402C159110408 @default.
• W2967066402 hasConceptScore W2967066402C16005928 @default.
• W2967066402 hasConceptScore W2967066402C168563851 @default.
• W2967066402 hasConceptScore W2967066402C2776173921 @default.
• W2967066402 hasConceptScore W2967066402C2777011040 @default.
• W2967066402 hasConceptScore W2967066402C2779951463 @default.
• W2967066402 hasConceptScore W2967066402C2780564577 @default.
• W2967066402 hasConceptScore W2967066402C3020604521 @default.
• W2967066402 hasConceptScore W2967066402C71924100 @default.
• W2967066402 hasConceptScore W2967066402C90924648 @default.
• W2967066402 hasIssue "12" @default.
• W2967066402 hasLocation W29670664021 @default.
• W2967066402 hasLocation W29670664022 @default.
• W2967066402 hasLocation W29670664023 @default.
• W2967066402 hasLocation W29670664024 @default.
• W2967066402 hasOpenAccess W2967066402 @default.
• W2967066402 hasPrimaryLocation W29670664021 @default.
• W2967066402 hasRelatedWork W1978428707 @default.
• W2967066402 hasRelatedWork W2361583958 @default.
• W2967066402 hasRelatedWork W2461170543 @default.
• W2967066402 hasRelatedWork W2462324581 @default.
• W2967066402 hasRelatedWork W2602145888 @default.
• W2967066402 hasRelatedWork W2998923669 @default.
• W2967066402 hasRelatedWork W4247679967 @default.
• W2967066402 hasRelatedWork W4255680485 @default.
• W2967066402 hasRelatedWork W4297878981 @default.
• W2967066402 hasRelatedWork W4321997075 @default.
• W2967066402 hasVolume "33" @default.
• W2967066402 isParatext "false" @default.
• W2967066402 isRetracted "false" @default.
• W2967066402 magId "2967066402" @default.
• W2967066402 workType "article" @default.